COVID-19 in chronic myeloid leukemia patients in Latin America.
Leuk Lymphoma
; 62(13): 3212-3218, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1307417
ABSTRACT
This observational, multicenter study aimed to report the clinical evolution of COVID-19 in patients with chronic myeloid leukemia in Latin America. A total of 92 patients presented with COVID-19 between March and December 2020, 26% of whom were severe or critical. The median age at COVID-19 diagnosis was 48 years (22-79 years), 32% were 60 years or older, and 61% were male. Thirty-nine patients presented with at least one comorbidity (42.3%). Eighty-one patients recovered (88%), and 11 (11.9%) died from COVID-19. There was one case of reinfection. Patients with a major molecular response presented superior overall survival compared to patients with no major molecular response (91 vs. 61%, respectively; p = 0.004). Patients in treatment-free remission and receiving tyrosine kinase inhibitors showed higher survival rates than patients who underwent hematopoietic stem cell transplantation and those who did not receive tyrosine kinase inhibitors (100, 89, 50, and 33%, respectively; p < 0.001).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
COVID-19
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
/
Male
Language:
English
Journal:
Leuk Lymphoma
Journal subject:
Hematology
/
Neoplasms
Year:
2021
Document Type:
Article
Affiliation country:
10428194.2021.1950709
Similar
MEDLINE
...
LILACS
LIS